We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

64 hedge funds and large institutions have $82.5M invested in Oncternal Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 14

100% more capital invested

Capital invested by funds: $41.2M → $82.5M (+$41.2M)

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

23% more funds holding

Funds holding: 52 → 64 (+12)

51% less call options, than puts

Call options by funds: $1.41M | Put options by funds: $2.85M

Holders
64
Holders Change
+12
Holders Change %
+23.08%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
18
Reduced
12
Closed
14
Calls
$1.41M
Puts
$2.85M
Net Calls
-$1.44M
Net Calls Change
-$1.51M

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$6.33M
2
BlackRock
BlackRock
New York
+$4.84M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.14M
4
Ameriprise
Ameriprise
Minnesota
+$2.88M
5
PHP
Parkman Healthcare Partners
Connecticut
+$2.66M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$3.77M
2
6CM
683 Capital Management
New York
-$3.57M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.78M
4
EP
Eversept Partners
New York
-$1.69M
5
ACM
Altium Capital Management
New York
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$14.7M +$532K +4,026 +5%
BlackRock
2
BlackRock
New York
$8.95M +$4.84M +36,632 +214%
Invesco
3
Invesco
Georgia
$7.97M +$6.33M +47,897 New
PHP
4
Parkman Healthcare Partners
Connecticut
$6.48M +$2.66M +20,100 +107%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$4.17M +$3.14M +23,728 +1,755%
IC
6
Ikarian Capital
Texas
$3.83M -$3.77M -28,500 -55%
Ameriprise
7
Ameriprise
Minnesota
$3.62M +$2.88M +21,761 New
Millennium Management
8
Millennium Management
New York
$3.29M +$517K +3,908 +25%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$3.03M +$1.46M +11,022 +154%
BJL
10
Brighton Jones LLC
Washington
$2.77M +$2.2M +16,644 New
SCM
11
Sio Capital Management
New York
$2.69M – – –
ACM
12
Altium Capital Management
New York
$1.47M -$1.56M -11,769 -57%
DY
13
Dowling & Yahnke
California
$1.25M – – –
Citadel Advisors
14
Citadel Advisors
Florida
$1.2M +$956K +7,229 New
ACA
15
Apis Capital Advisors
New York
$1.2M -$238K -1,800 -20%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$1.19M +$845K +6,387 New
Two Sigma Investments
17
Two Sigma Investments
New York
$923K -$490K -3,707 -40%
UCFA
18
United Capital Financial Advisors
Texas
$920K +$172K +1,300 +31%
Goldman Sachs
19
Goldman Sachs
New York
$899K +$715K +5,405 New
SSA
20
Schonfeld Strategic Advisors
New York
$842K +$201K +1,520 +43%
Envestnet Asset Management
21
Envestnet Asset Management
Illinois
$833K +$662K +5,004 New
Mercer Global Advisors
22
Mercer Global Advisors
Colorado
$833K +$662K +5,007 New
ECM
23
ExodusPoint Capital Management
New York
$787K +$625K +4,728 New
Belvedere Trading
24
Belvedere Trading
Illinois
$731K +$581K +4,393 New
Northern Trust
25
Northern Trust
Illinois
$703K +$265K +2,006 +90%
1
2 3 4

ONCT Hedge Fund Activity: Q1 2021 in Review

64 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2021, worth a combined $82.5M — up 100% from $41.2M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ONCT positions and 14 closed out — a net gain of 15 holders — while 18 added to existing stakes and 12 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $6.33M. The largest seller was Ikarian Capital, cutting an estimated $3.77M.

  • 64 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $82.5M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2021, up 100% quarter-over-quarter.
  • 29 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +15 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2021 was Invesco, an estimated $6.33M added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2021 was Ikarian Capital, an estimated $3.77M sold.

Based on aggregated 13F filings for Q1 2021.